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SUMMARY 
 
International Circumpolar Surveillance (ICS) is a population-based surveillance system for invasive bacterial 
diseases established in the U.S. Arctic, Northern Canada, Greenland, Iceland, Norway, Finland, and Northern 
Sweden.  Data collection began in 1999 and includes information on disease caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B Streptococcus (GAS, GBS).  
This report reviews the data collected for the year 2012. 
 
Data on invasive disease with the organism S. pneumoniae are collected from all participating countries.  A total 
of 1,647 cases of invasive pneumococcal disease were identified in 2012.  Overall, rates of invasive S. 
pneumoniae were highest in individuals less than 2 years of age or in persons 65 years and older.  Case fatality 
ratios ranged from 0-14%.  Race and ethnicity data are collected only in N. Canada and the U.S. Arctic; rates of 
invasive pneumococcal disease in Northern Canadian Aboriginals and U.S. Arctic Native populations were 27 
and 48 cases per 100,000 population, respectively, which are similar to the 2011 rates in these populations.  
Pneumonia and bacteremia were the most common clinical presentations; cigarette smoking, alcohol abuse, and 
chronic lung disease were the most common risk factors.  The most common S. pneumoniae serotype in Iceland 
was 22, in Greenland it was serotypes 4 and 22F, in N. Canada and N. Sweden it was 7F and in the U. S. Arctic 
the most common serotypes were 3 and 22F. 
 
Data on invasive disease due to H. influenzae, N. meningitidis, and groups A and B Streptococcus are currently 
collected in Greenland, Northern Canada, Northern Sweden and the U.S. Arctic; Norway also contributes data 
on cases of N. meningitidis and H. influenzae.  A total of 112 H. influenzae cases, 32 N. meningitidis cases, 76 
GAS cases, and 33 GBS cases were reported in 2012.  In general, the highest rates of disease for all organisms 
occurred in N. Canada Aboriginal or Alaska Native persons less than two years of age and persons 65 and older. 
 
Surveillance Organisms Reported by Country, ICS 2012 Data 
 
Country 
S. pneumoniae 
n (rate*) 
H. influenzae 
n (rate*) 
N. meningitidis 
n (rate*) 
GAS 
n (rate*) 
GBS 
n (rate*) 
Finland 751 (13.8) N/A N/A N/A N/A 
Greenland 7 (12.3) 1 (1.2) 0 (0) 0 (0) 0 (0) 
Iceland 28 (8.8) N/A N/A N/A N/A 
N. Canada 26 (16.6) 13 (8.3) 2 (1.3) 14 (9) 0 (0) 
N. Sweden 79 (15.5)† 5 (2)‡ 4 (1.6)‡ 14 (5.6)‡ 0 (0)‡ 
Norway 626 (12.6) 78 (1.6) 24 (0.5) N/A N/A 
U.S. Arctic 130 (17.8) 15 (2.1) 2 (0.3) 48 (6.6) 33 (4.5) 
Total 1,647 (13.5) 112 (1.8) 32 (0.5) 76 (6.4) 33 (2.8) 
*Cases per 100,000 
† Norbotten & Vasterbotten 
‡Norbotten  
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INTRODUCTION 
 
In January, 1999, the United States and Canada began international cooperative population-based surveillance 
for invasive S. pneumoniae by all laboratories serving residents of the North American Arctic.  In January, 
2000, this surveillance system expanded to include invasive diseases with the following organisms:  H. 
influenzae (all types), N. meningitidis, GAS, and GBS.  These pathogens were selected for ICS because rates of 
these diseases are elevated in indigenous peoples of the north, strains demonstrate resistance to commonly used 
antibiotics, they are routinely cultured in clinical laboratories, and clinically important serotypes of S. 
pneumoniae, H. influenzae, and N. meningitidis are vaccine preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000; Iceland, Norway (including Svalbard), and 
Finland joined in 2001; the Northern Sweden regions of Norbotten and Vasterbotten joined in 2003 and 2006, 
respectively.   
 
GOALS 
 
The goal of ICS is to establish an integrated network of hospital and public health facilities throughout the 
Arctic countries to monitor infectious diseases of concern.  Linking public health facilities within Arctic nations 
will allow for the collection and sharing of uniform laboratory and epidemiological data that will describe the 
prevalence of infectious diseases in Arctic populations and assist in the formulation of prevention and control 
strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by S. pneumoniae.  
This bacterium causes pneumonia, meningitis, and bacteremia in both the very young and the elderly.  Once 
easily treated with antibiotics, this bacterium has become resistant to commonly used antibiotics.  This is of 
great concern to the public health community and is increasingly a target for surveillance by many countries 
worldwide.  A polysaccharide vaccine is available for use in persons two years of age and older.  A conjugate 
vaccine for infants has been developed and is licensed for use in the U.S., Canada, and the European Union.  
The fact that diseases caused by S. pneumoniae were already being monitored by many public health authorities 
within the Arctic states made establishing a circumpolar surveillance system for this infection feasible.  In 
addition, due to the availability of polysaccharide and conjugate vaccines, much of the morbidity and mortality 
caused by S. pneumoniae is currently preventable. 
 
ICS objectives include: 
 
• Identify key public health contacts within Arctic countries.  These persons should be familiar with infectious 
disease surveillance systems in place (particularly surveillance systems for diseases caused by S. 
pneumoniae) in the member country.  Through correspondence and working group meetings, the scope and 
gaps of the surveillance systems are determined. 
 
• Determine the comparability of laboratory and data collection methods, and negotiate standard protocols 
and quality control programs. 
 
• Share and report data in agreed upon formats. 
 
• Form a working group of key laboratory and public health contacts to coordinate pneumococcal surveillance 
within their respective jurisdictions.  This group meets on a regular basis to review problems, progress, 
compliance, report generation, and future plans. 
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• Form a steering committee of national Arctic health experts to coordinate new objectives and initiatives 
within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well as prevention 
and control programs can be added.  Other infectious diseases of circumpolar community concern include:  
other invasive bacterial diseases (caused by H. influenzae, N. meningitidis, GAS, and GBS), tuberculosis, HIV, 
hepatitis, foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children such 
as those caused by respiratory syncytial virus, and chronic conditions related to infectious agents (hepatitis B 
virus and liver cancer, human papilloma virus and cervical cancer, H. pylori and stomach cancer), and climate 
sensitive diseases.  In addition, the surveillance model developed by this program for infectious disease may be 
adapted to monitor other non-infectious human health priorities of community concern. 
 
METHODS 
 
ICS is coordinated by personnel at the Arctic Investigations Program (AIP), Centers for Disease Control and 
Prevention, in Anchorage, Alaska. 
 
A case of invasive S. pneumoniae, H. influenzae, N. meningitidis, GAS or GBS is defined by the isolation of the 
bacteria from a normally sterile site, (including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint 
fluid) that has been taken from a resident of the surveillance area. 
 
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected continually by 
ICS, while in Greenland, Iceland, Northern Sweden, Norway, and Finland, summary data are submitted to ICS 
in aggregate at the end of the year. 
 
Surveillance System Description by Country/Region 
 
The following table outlines the organisms reported and data provided by each country or region. 
 
Data Provided by Country/Region, ICS 2012 
Country S
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Finland X            
Greenland X X X X X X X   X   
Iceland X     X X   X  X 
N. Canada X X X X X X X X X X X X 
N. Sweden X X X X X  X     X 
Norway X X X   X* X   X X  
U.S. Arctic X X X X X X X X X X X X 
*Serotypes/serogroups reported for Hi/Nm only 
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Finland 
 
Case level data was not reported from Finland for 2012.  Overall numbers of invasive S. pneumoniae cases were 
obtained from the National Institute for Health and Welfare report “Infectious Diseases in Finland 2012” [1]. 
 
• 23 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Finland. 
o All invasive isolates of S. pneumoniae submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
 
• Population estimates for 2012 were obtained from the website http://www.stat.fi  
 
Greenland 
 
• 15 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Greenland. 
o All invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS submitted to 
reference laboratories in Nuuk and Copenhagen. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution at the central 
laboratory at Queen Ingrid’s Hospital in Nuuk. 
 
• Serotyping was performed at the Statens Serum Institute in Copenhagen, Denmark, by the Quellung 
method. 
 
• Clinical and demographic data for every case of invasive S. pneumoniae, H. influenzae, N. meningitidis, 
GAS, and GBS was collected by public health authorities at the end of the year and entered onto a 
standardized collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2012 were obtained from the website http://www.stat.gl  
 
Iceland 
 
• 10 district hospital laboratories and one regional laboratory participate in ICS. 
o Provide diagnostic microbiology services for all residents of Iceland. 
o All invasive isolates of S. pneumoniae submitted to the reference hospital in Reykjavik. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by disc diffusion method at the 
Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional hospital in Akureyri.  
All oxacillin resistant isolates are then analyzed by E test. 
 
• Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum Institute. 
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• Clinical and demographic data for every case of invasive S. pneumoniae was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in Greenland, 
Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2012 were obtained from the website http://www.statice.is  
 
Northern Canada 
 
• 14 Canadian laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of the Yukon Territory, Northwest Territories, 
Nunavut, Northern Quebec, and Northern Laborador. 
o Submit all invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS to one of 
two reference laboratories in Canada. 
o S. pneumoniae, H. influenzae, GAS, and GBS isolates are serotyped by the Quellung method using 
Statens Serum Institute antisera. 
 
• Antimicrobial susceptibility of S. pneumoniae, GAS, and GBS isolates was tested by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Communicable disease consultants located within one of the five regions of Northern Canada provided 
clinical and demographic information on the same collection form (BDSF) used in Greenland, Iceland, and 
the U.S. Arctic. 
 
• Population estimates for 2012 were obtained from the website http://www.statcan.ca 
 
Northern Sweden 
 
• 1 district laboratory participates in ICS. 
o Provides diagnostic microbiology services for all residents of Norrbotten and Vasterbotten counties. 
o The main reference laboratory is at the Swedish Institute for Infectious Disease Control in Stockholm. 
o Isolates are serotyped by the Quellung method. 
• Antimicrobial susceptibility testing was by disc diffusion at the University Hospital in Umea and Sunderby 
Hospital in Lulea. 
 
• Population estimates for 2012 were obtained from the website http://www.scb.se/default____2154.asp 
 
Norway 
 
• 33 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Norway. 
o All invasive isolates of S. pneumoniae submitted to one of two reference laboratories in Oslo or Tromsö. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed using the disc diffusion method 
at district hospital laboratories, the reference laboratory in Tromsö or the main national laboratory in Oslo. 
 
• Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 
 
• Population estimates for 2012 were obtained from the website http://www.ssb.no  
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U.S. Arctic 
 
• 23 laboratories providing diagnostic services to residents of Alaska submitted to AIP isolates of S. 
pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS cultured in blood, cerebrospinal fluid, or from 
other sterile sites. 
o S. pneumoniae and H. influenzae isolates are serotyped by the Quellung method using Statens Serum 
Institute antisera. 
o Serogroup testing of N. meningitidis was done using real-time PCR to detect the ctaA gene (capsule 
transport), as well as the genes required for serogroup-specfic capsule biosynthesis.   
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed at AIP by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Clinical and demographic information on each case-patient is recorded by AIP research nurses onto the 
same collection form (BDSF) used in Greenland, Iceland, and Northern Canada. 
 
• Population estimates for 2012 were obtained from the website http://www.labor.state.ak.us 
 
Quality Control 
 
Streptococcus pneumoniae:  Clinical laboratories in the U.S. Arctic and N. Canada forward isolates from 
patients with invasive pneumococcal disease to reference laboratories in Alaska and Canada respectively.  To 
ensure inter-laboratory comparability of S. pneumoniae serotyping and antimicrobial susceptibility testing 
between two reference laboratories in Canada (Alberta and Quebec) and one in the U.S. (Alaska), the ICS S. 
pneumoniae inter-laboratory quality control (QC) program was established in 1999.  Statens Serum Institute, 
Copenhagen, Denmark, joined the program in 2004. Each reference laboratory is responsible for exporting one 
QC panel of seven S. pneumoniae isolates every other year to each of the other laboratories using a 
transportation medium of their choice for a total of 14 Strep pneumoniae isolates in 2012 [2]. 
 
Neisseria meningitidis/Haemophilus influenzae:  An interlaboratory quality control program for Neisseria 
meningitidis and Haemophilus influenzae was established in 2005.  Participating laboratories include the 
National Microbiology Laboratory, Winnipeg, Manitoba, Canada; Arctic Investigations Program, Anchorage, 
Alaska, USA; Laboratoire Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada; National 
Centre for Streptococcus, Edmonton, Alberta, Canada; and Statens Serum Institut, Copenhagen, Denmark.  
Strain panels are distributed twice a year from the National Microbiology Laboratory or Arctic Investigations 
Program [3]. 
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Participating Countries, ICS 2012 
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RESULTS 
 
Streptococcus pneumoniae 
 
Case Demographics 
 
A total of 1,647 cases of invasive disease caused by S. pneumoniae were reported to ICS during 2012 by 
Finland, Greenland, Iceland, N. Canada, N. Sweden, Norway, and the U.S. Arctic.  The highest rates of disease 
(17.8 per 100,000) occurred in the U.S. Arctic and the lowest in Iceland (8.8 per 100,000) with an overall rate 
for the ICS circumpolar region of 13.5 per 100,000; 52% of all cases occurred in males.  The median age of 
cases overall was 63.5 years with the lowest median age in N. Canada (26.4 years) and the highest in N. Sweden 
(67 years).  Case fatality ratios ranged from 0% in Greenland to 14% in Iceland; the overall case fatality ratio 
was 14%. 
 
Streptococcus pneumoniae Case Demographics, ICS 2012 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR**) 
Finland 5,426,674 751 13.8 † † † 
Greenland 56,749 7 12.3 5 (71) 64.4 (1.7-84) 0 (0) 
Iceland 319,575 28 8.8 13 (46) 50.5 (22-90) 4 (14) 
N. Canada 156,286 26 16.6 6 (23) 26.4 (0.3-79) 3 (13)b 
N. Sweden 508,592a 79 15.5 41 (52) 67 (21-94) ‡ 
Norway 4,985,870 626 12.6 318 (51) 65.9 (0-99.3) 46 (13)b 
U.S. Arctic 731,827 130 17.8 81 (62) 57 (0.1-99.5) 17 (13)b 
Total 12,185,573 1,647 13.5 464 (52) 63.4 (0-99.5) 70 (13) 
*Number of cases per 100,000 per year 
** Case fatality ratio 
†Data not reported from Finland 
‡Case outcomes not reported from N. Sweden 
a Population for Norbotten and Vasterbotten 
b Case outcomes unknown in 2 cases from N. Canada, 283 cases from Norway, 1 case from U.S. Arctic 
 
Streptococcus pneumoniae by Age Category, ICS 2012 Data 
Age  Greenland Iceland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Pop 1,651 9,345 5,519 9,912 122,987 21,568 
N (%)* 1 (14) 0 (0) 5 (19) 0 (0) 10 (2) 13 (10) 
Rate† 60.6 0 90.6 0 8.1 60.3 
2-19 
yrs 
Pop 15,243 80,125 45,238 98,292 1,125,578 186,994 
N (%)* 1 (14) 0 (0) 7 (27) 0 (0) 18 (3) 10 (8) 
Rate† 6.6 0 15.5 0 1.6 5.4 
20-64 
yrs 
Pop 35,760 189,783 96,064 293,166 2,969,291 459,476 
N (%)* 2 (29) 20 (71) 12 (46) 37 (47) 270 (43) 76 (58) 
Rate† 5.6 10.5 12.5 12.6 9.1 16.5 
65+ 
yrs 
Pop 4,095 40,322 9,465 107,222 768,014 63,789 
N (%)* 3 (43) 8 (29) 2 (8) 42 (53) 328 (52) 31 (24) 
Rate† 73.3 19.8 21.1 39.2 42.7 48.6 
All 
ages 
Pop 56,749 319,575 156,286 508,592 4,985,870 731,827 
N 7 28 26 79 626 130 
Rate† 12.3 8.8 16.6 15.5 12.6 17.8 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
 9 
 
When stratified by age, the highest rates of disease in most countries occurred either in those cases less than two 
years of age or in cases 65+ years of age.  In Norway, the highest rates were in the 20-64 years and 65+ years of 
age categories. 
 
Seasonality 
 
S. pneumoniae was identified throughout the year in 2012 in each country.  For all countries except N. Canada, 
higher proportions of disease were seen in the first quarter with declines in the second quarter and rising again 
in either the third or fourth quarter of the year.  In N Canada, the highest proportion of cases were seen in the 
third quarter of the year and lowest in the fourth quarter. 
 
Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  Rates of invasive pneumococcal 
disease were higher overall in Aboriginal and AK Native populations than in non-Aboriginal and non-AK 
Native populations.  The highest rates of disease occurred in Aboriginal and AK Native children less than 2 
years of age in N. Canada and the U.S. Arctic.   
 
Streptococcus pneumoniae by Race and Age Categories, ICS 2012 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,005 1,514 6,196 15,372 Cases (rate‡) 4 (99.9) 1 (66.1) 11 (177.5) 2 (13) 
2-19 Population 33,323 11,915 49,706 137,288 Cases (rate‡) 7 (21) 0 (0) 6 (12.1) 4 (2.9) 
20-64 Population 47,060 49,004 77,546 381,930 Cases (rate‡) 11 (23.4) 1 (2) 38 (49) 38 (10) 
65+ Population 4,687 4,778 8.997 54,792 Cases (rate‡) 2 (42.7) 0 (0) 13 (144.5) 18 (32.9) 
All 
Ages 
Population 89,075 67,210 142,435 589,392 
Cases (rate‡) 24 (26.9) 2 (3) 68 (47.7) 62 (10.5) 
‡Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the pneumococcal infection was recorded as the primary clinical 
presentation. The most common clinical presentations associated with S. pneumoniae were pneumonia, 
bacteremia, and meningitis. In Greenland, N. Canada, and the U.S. Arctic the clinical presentation reported 
most often was pneumonia (100%, 65%, and 70%, respectively), in N. Sweden and Norway it was bacteremia 
(98% and 48%, respectively).  
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Clinical Presentation of Reported Streptococcus pneumoniae Cases, ICS 2012 Data 
 Greenland 
n (%) 
Iceland 
n (%) 
N Canada 
n (%) 
N Sweden** 
n (%) 
Norway 
n (%) 
US Arctic 
n (%) 
Pneumonia* 7 (100) 0 (0) 17 (65) 0 (0) 235 (38) 91 (70) 
Bacteremia 0 (0) 23 (82) 7 (27) 40 (98) 299 (48) 18 (14) 
Meningitis 0 (0) 5 (18) 0 (0) 1 (2) 57 (9) 10 (8) 
Empyema 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (3) 
Peritonitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (1.5) 
Septic arthritis 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 
Endocarditis 0 (0) 0 (0) 1 (4) 0 (0) 0 (0) 2 (1.5) 
Pericarditis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (1.5) 
Cellulitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.5) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 31 (5) 0 (0) 
Unknown 0 (0) 0 (0) 1 (4) 0 (0) 3 (1) 0 (0) 
Total Cases 7 28 26 41 626 130 
*with bacteremia 
**Clinical presentation data reported from Vasterbotten only 
 
Risk Factors 
 
N. Canada and the U.S. Arctic reported medical conditions or risk factors associated with S. pneumoniae.  In 
adults 18 years and older, cigarette smoking and alcohol abuse were the most common associated conditions in 
the U.S. Arctic; alcohol abuse and diabetes were the most commonly reported in N. Canada.  
 
Streptococcus pneumoniae Risk Factor/Medical Conditions in Adults*, ICS 2012 Data† 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 2 (14) 46 (43) 
Alcohol Abuse 4 (29) 31 (29) 
Chronic Lung Disease and/or Asthma 1 (7) 30 (28) 
Immunosuppressive Therapy 0 (0) 3 (3) 
Diabetes 3 (21) 18 (17) 
Injection Drug Use 0 (0) 1 (1) 
Asplenia 1 (7) 1 (1) 
Total Adult* Cases 14 108 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Vaccination Policy 
 
In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal polysaccharide vaccine 
(PS23) is recommended for persons over 60 years (Iceland) or over 65 years of age (Finland, N. Canada, 
Norway, U.S. Arctic), and to persons greater than two years of age (Finland, Iceland, Norway, U.S. Arctic) or 
greater than five years of age (N. Canada) with specific medical problems.  The vaccine is only recommended 
for certain risk groups in N. Sweden.  Three pneumococcal conjugate vaccines (PCV), PCV7, PCV10, and 
PCV13, for use in children under the age of 2 years have been used in ICS regions since 2001.  Vaccines used 
and years introduced are presented in the table below. 
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Pneumococcal Vaccines Introduced, ICS 2012 Data 
 Finland Greenland Iceland N Canada N Sweden Norway US Arctic 
PCV7    2002-2006* 2007 2007 2001 
PCV10 2010  2011 2009-2010*    
PCV13  2010  2010-2011* 2010 2011 2010 
PS23 † 1996 † 1988 1994 † 1983 
*PCV7 – N Quebec and Nunavut (2002), Newfoundland and Yukon (2005), Northwest Territory (2006); PCV10 – Nunavut (2010); 
PCV13 – N Quebec (2011) 
†PS23 used but year of introduction unknown 
 
Vaccination Status 
 
Thirteen percent of S. pneumoniae cases in children less than 2 years of age with known vaccination status were 
vaccinated with a PCV in Norway; in N. Canada and the U.S. Arctic, 100% of children with known vaccine 
status were vaccinated.  Only 4% of cases eligible for PS23 in Norway were vaccinated indicating much less 
frequent use of this vaccine than in N. Canada and the U.S. Arctic.  Vaccine coverage data were not reported 
from Iceland and N. Sweden.   
 
Streptococcus pneumoniae Case Vaccination Status for Pneumococcal Vaccine, ICS 2012 Data 
 N. Canada Norway U.S. Arctic 
Total cases eligible for PCV vaccine* 5 10 13 
Vaccine status known in cases eligible for PCV 3 10 13 
Cases eligible for PCV vaccinated (%)† 3 (100%) 7 (70%) 11 (85%) 
Total cases eligible for PS23 vaccine‡ 2 328 31 
Vaccine status known in cases eligible for PS23 1 106 28 
Cases eligible for PS23 vaccinated (%)† 1 (100%) 5 (5%) 19 (68%) 
*Children less than 2 years of age 
†Percent of vaccine status known cases 
‡Adults 65 years and older 
 
Serotypes 
 
The S. pneumoniae serotypes reported by ICS regions in 2012 are listed in the following table; yellow 
highlights the most common serotypes in each country.      
 
 Streptococcus pneumoniae Serotypes by Country, ICS 2012 Data 
Serotype 
Greenland 
n (%†) 
Iceland 
n (%†) 
N. Canada 
(%†) 
N. Sweden* 
n (%†) 
U.S. Arctic 
n (%†) 
1‡ 1 (14) 3 (11) 0 (0) 1 (3) 0 (0) 
3‡ 0 (0) 2 (7) 0 (0) 2 (6) 12 (10) 
4‡ 2 (29) 1 (4) 1 (4) 2 (6) 0 (0) 
6A‡ 0 (0) 3 (11) 0 (0) 1 (3) 1 (1) 
6B‡ 1 (14) 1 (4) 0 (0) 2 (6) 0 (0) 
6C 0 (0) 0 (0) 0 (0) 0 (0) 4 (3) 
7C 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
7F‡ 0 (0) 0 (0) 4 (17) 4 (13) 10 (8) 
8 0 (0) 0 (0) 1 (4) 2 (6) 5 (4) 
9N 0 (0) 0 (0) 0 (0) 1 (3) 3 (2) 
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Serotype 
Greenland 
n (%†) 
Iceland 
n (%†) 
N. Canada 
(%†) 
N. Sweden* 
n (%†) 
U.S. Arctic 
n (%†) 
9V‡ 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 
10A 0 (0) 0 (0) 3 (13) 0 (0) 3 (2) 
11 0 (0) 2 (7) 0 (0) 0 (0) 0 (0) 
11A 0 (0) 0 (0) 1 (4) 2 (6) 2 (2) 
12F 1 (14) 0 (0) 0 (0) 0 (0) 8 (7) 
14‡ 0 (0) 3 (11) 0 (0) 0 (0) 0 (0) 
15 0 (0) 1 (4) 0 (0) 0 (0) 0 (0) 
15A 0 (0) 0 (0) 1 (4) 0 (0) 7 (6) 
15C 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
16F 0 (0) 0 (0) 1 (4) 0 (0) 2 (2) 
17F 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
19A‡ 0 (0) 0 (0) 3 (13) 3 (9) 8 (7) 
19F‡ 0 (0) 1 (4) 0 (0) 3 (9) 2 (2) 
20 0 (0) 1 (4) 0 (0) 0 (0) 9 (7) 
21 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
22 0 (0) 4 (14) 0 (0) 0 (0) 0 (0) 
22A 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
22F 2 (29) 0 (0) 3 (13) 3 (9) 12 (10) 
23A 0 (0) 1 (4) 1 (4) 1 (3) 5 (4) 
23B 0 (0) 0 (0) 1 (4) 0 (0) 2 (2) 
23F 0 (0) 3 (11) 0 (0) 2 (6) 0 (0) 
31 0 (0) 0 (0) 0 (0) 0 (0) 6 (5) 
33F 0 (0) 0 (0) 1 (4) 0 (0) 8 (7) 
35B 0 (0) 1 (4) 1 (4) 0 (0) 4 (3) 
35F 0 (0) 0 (0) 0 (0) 2 (6) 2 (2) 
38 0 (0) 0 (0) 1 (4) 0 (0) 2 (2) 
Non-viable 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
# Isolates 
Serotyped 7 28 23 32 122 
*Serogroup level data from Vasterbotten 
†Percent of total isolates serotyped 
‡Serotype included in PCV 
 
Cases and Deaths with Vaccine Serotypes 
 
For the countries reporting serotype data, at least 71% of S. pneumoniae cases in persons ≥ 2 years of age had a 
serotype that was included in the 23-valent polysaccharide vaccine.  Eight percent to 100% of Strep 
pneumoniae cases in children < 2 years of age had a serotype contained in the PCV13 vaccine.  The proportion 
of deaths with serotypes in the 23-valent polysaccharide vaccine related to S. pneumoniae ranged from 0% to 
100%. 
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Proportion of Cases/Deaths with Invasive Pneumococcal Disease Vaccine Serotypes, ICS 2012 Data 
 
*Number of isolates serotyped by country by age group 
**7 isolates tested to serogroup level only 
‡Percentage of total death 
†Outcomes not reported 
 
Outcome 
 
A total of 70 deaths associated with S. pneumoniae were reported to ICS in 2012.  Overall, the highest case 
fatality ratio (CFR) occurred in persons 65+ years of age (18%).  Finland and N. Sweden did not report outcome 
data. 
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2012 Data 
  <2 years 2-19 years 20-64 years 65+ years All Ages 
Greenland Deaths/Cases* (CFR) 
0/1 
(0%) 
0/1 
(0%) 
0/2 
(0%) 
0/3 
(0%) 
0/7 
(0%) 
Iceland Deaths/Cases* (CFR) 
0/0 
(0%) 
0/0 
(0%) 
2/20 
(10%) 
2/8 
(25%) 
4/28 
(14%) 
N. Canada Deaths/Cases* (CFR) 
0/4† 
(0%) 
0/7 
(0%) 
3/11† 
(28%) 
0/2 
(0%) 
3/24 
(13%) 
Norway Deaths/Cases* (CFR) 
0/5† 
(0%) 
0/14† 
(0%) 
11/149† 
(7%) 
35/175† 
(20%) 
46/343 
(13%) 
U.S. Arctic Deaths/Cases* (CFR) 
0/13 
(0%) 
0/10 
(0%) 
14/75 
(19%) 
3/31 
(10%) 
17/129 
(13%) 
Total Deaths/Cases* (CFR) 
0/23 
(0%) 
0/32 
(0%) 
30/257 
(12%) 
40/219 
(18%) 
70/531 
(13%) 
*Cases with known outcome.   
†Outcome unknown in (1) N Canada, (5) Norway cases < 2 years; (4) Norway cases 2-19 years; (1) N Canada, (121) Norway, (1) US 
Arctic cases 20-64 years; (153) Norway cases 65+ years 
 
Antimicrobial Susceptibility 
 
In 2012, antimicrobial susceptibility results were reported to ICS from Iceland, N. Canada, N. Sweden and the 
U.S. Arctic.  The following table outlines for each country the antibiotics tested, the number of isolates reported 
tested for each antibiotic and the proportion (NS%) of isolates tested that showed any level of non-
susceptibility. 
 
 
 
 
 Greenland 
n/Denom* 
(%) 
Iceland 
n/Denom* 
(%) 
N. Canada 
n/Denom* 
(%) 
N. Sweden 
n/Denom* 
(%) 
U.S. Arctic 
n/Denom* 
(%) 
Cases ≥ 2 years old with serotype in the 
23-valent pneumococcal polysaccharide 
vaccine 
6/6 
(100) 
15/20** 
(75) 
15/19 
(79) 
28/32 
(88) 
77/109 
(71) 
Cases < 2 years old with serotype in the 
13-valent pneumococcal conjugate 
vaccine 
1/1 
(100) No cases 
2/4 
(50) No cases 
1/13 
(8) 
Deaths (all ages) for which the serotype 
was contained in the 23-valent 
pneumococcal vaccine 
0 (0‡) 1 (25‡) 3 (100‡) † 6 (35‡) 
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Streptococcus pneumoniae Antibiotic Susceptibility Testing, ICS 2012 Data 
 Antibiotic 
Iceland 
n (NS%) 
N. Canada 
n (NS%) 
N. Sweden 
n (NS%) 
U.S. Arctic 
n (NS%) 
Ceftriaxone 28 (0%) 24 (4%) - 121 (8%) 
Chloramphenicol 28 (0%) 21 (0%) - 121 (3%) 
Clindamycin - 21 (4%) - 121 (11%) 
Erythromycin 28 (7%) 21 (12%) 41 (1%) 121 (21%) 
Levofloxacin - 21 (0%) - 121 (1%) 
Penicillin 28 (4%) 24 (4%) 40 (0%) 121 (19%) 
Rifampin - - - 121 (1%) 
Tetracycline - - -  121 (12%) 
TMP Sulfa* 28 (18%) 21 (12%) 38 (4%) 121 (18%)  
Vancomycin - 24 (0%) - 121 (0%) 
*Trimethoprimsulfamethoxizole 
 
Of the antibiotics tested, the largest numbers of isolates were resistant to penicillin, TMP-Sulfa and 
erythromycin.  Results by country for each of these antibiotics are shown in the tables below.  In the U.S. 
Arctic, 22 isolates comprised of 9 serotypes (3, 6A, 6C, 15A, 19A, 23A, 23B, 33F, 35B) showed multi-drug 
resistance.  Serotypes 15A and 19A comprised the largest proportion (n = 10 (5 of each serotype), 46%) of the 
multi-drug resistant isolates and all of isolates with these serotypes were resistant to three or more antibiotics.  
In N. Canada, one serotype 19A isolate was resistant to four antibiotics.  In Iceland, 5 isolates including 
serotypes 6B, 15, 19F, and 23F were resistant to more than one antibiotic.   
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2012 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Iceland 28 1 (4%) 19F (1) 0 (0%)  
N. Canada 24 1 (4%) 19A (1) 0 (0%)  
N. Sweden‡ 40 0 (0%)  0 (0%)  
U.S. Arctic 121 15 (12%) 15A (5), 23A (4), 6C (2), 19A (2), 6A (1), 23B (1) 8 (7%) 19A (4), 35B (4) 
*I=Intermediate resistance, R=Fully resistant 
†Serotypes not reported 
‡N. Sweden reported serogroups only 
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2012 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Iceland 28 2 (7%) 15 (1), 23F (1) 3 (11%) 6B (1), 19F (1), 23F (1) 
N. Canada 21 1 (5%) 33F (1) 2 (10%) 19A (2) 
N. Sweden† 38 3 (4%) 4 (1), 8 (1), 23F (1) 0 (0%)  
U.S. Arctic 121 12 (10%) 33F (4), 15A (3), 19A (2), 6C (1), 19F (1), 23A (1) 10 (8%) 
19A (5), 33F (3), 6C 
(1), 23B (1) 
*I=Intermediate resistance, R=Fully resistant 
†N. Sweden reported serogroups only 
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Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2012 Data 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes (n) 
Iceland 28 0 (0%)  2 (7%) 11 (1), 19F (1) 
N. Canada 21 0 (0%)  3 (14%) 19A (1), 23A (1), 33F (1) 
N. Sweden† 41 0 (0%)  1 (1%) 19A (1) 
U.S. Arctic 121 0 (0%)  25 (21%) 15A (5), 31 (5), 19A (4), 6C (3), 33F (3), 3 (2), 22F (1), 23A (1) 
*I=Intermediate resistance, R=Fully resistant 
†N. Sweden reported serogroups only 
 
Quality Control 
 
In 2012, two QC panels of seven S. pneumoniae isolates plus a control strain each were shipped and tested.  
Beginning in 2005, the MIC data was analyzed in two ways.  The first comparison is based on MIC data 
provided by the distributing laboratory and is the method used historically in the QC program.  The new 
methodology provides an analysis of MIC data for all the participating laboratories by using the modal MIC for 
each antibiotic-organism combination as the value to which the other data are compared.  The modal MIC is the 
MIC most frequently reported.  When two MIC values were reported with equal frequency, both were accepted 
as a modal value.  Antibiotic-organism combinations for which there was no consensus on a modal MIC were 
excluded from the analysis.  The rationale for initiating the second analysis recognizes that there is an allowable 
variation of one log2 dilution inherent for any MIC testing system.  This means that there is no one absolutely 
correct MIC value to which all others can be compared.  The modal MIC may be a better representation of this 
‘true’ value than any one laboratory can provide.  For Panel 2012-A, overall serotyping correlation was 100%. 
The modal MIC comparison resulted in an overall correlation of 99.4% with individual participant correlation 
ranging from 97.1%-100%.  Overall category agreement was 98.0% with individual participant agreement 
ranging from 97.1%-100%.  For Panel 2011-B, overall serotyping correlation was 100%.  The modal MIC 
comparison resulted in an overall correlation of 99.7%. Overall category agreement was 99% with individual 
participant agreement ranging from 96.8%-100% [1].   
 
Conclusions 
 
Streptococcus pneumoniae remains a major cause of invasive bacterial disease in circumpolar regions.  Disease 
rates are highest in indigenous populations.  All ICS regions have introduced either PCV10 or PCV13 into their 
vaccine schedules.  Monitoring the impact of these conjugate vaccines will be important to confirm 
effectiveness and provide support for continuing immunization programs. 
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Haemophilus influenzae 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of invasive 
H. influenzae disease during 2012.  A total of 112 cases of invasive disease caused by H. influenzae were 
reported to ICS during 2012.  The highest rate of disease among regions reporting cases was in N. Canada (8.3 
per 100,000) and the lowest in Norway (1.6/100,000).  Median age of cases was highest in Norway (67.2 years) 
and lowest in N. Canada (10.2 years).   
 
Haemophilus influenzae Case Demographics, ICS 2012 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,749 1 1.8 1 (100%) 1 case (41.6) 0 (0%) 
N. Canada 156,286 13 8.3 5 (39%) 10.2 (0.6-66.3) 0 (0%)‡ 
N. Sweden 248,548 5 2 1 (20%) 40 (31-97) ‡ 
Norway 4,985,870 78 1.6 35 (45%) 67.2 (1.1-93.3) 3 (8%)‡  
U.S. Arctic 731,827 15 2.1 9 (60%) 51 (0.4-78.9) 1 (7%) 
Total 6,179,280 112 1.8 51 (46%) 63.3 (0.4-97) 4 (6.5%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡ Case outcome unknown in (3) N. Canada, (42) Norway cases; N. Sweden did not report case outcomes 
 
When stratified by age, the highest rates of disease for N. Canada and the U.S. Arctic were in the <2 years age 
category; in Greenland and N. Sweden, the highest rate of disease was in the 20-64 year old category and in 
Norway, the highest rate of disease was in the 65+ years age category.   
 
Haemophilus influenzae by Age Category, ICS 2012 Data 
Age  Greenland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Population 1,651 5,519 4,473 122,987 21,568 
Cases (%)* 0 (0) 5 (38.5) 0 (0) 2 (3) 4 (27) 
Rate† 0 90.6 0 1.6 18.6 
2-19 yrs 
Population 15,243 45,238 47,031 1,125,578 186,994 
Cases (%)* 0 (0) 2 (15) 0 (0) 3 (4) 1 (7) 
Rate† 0 4.4 0 0.3 0.5 
20-64 yrs 
Population 35,760 96,064 141,785 2,969,291 459,476 
Cases (%)* 1 (100) 5 (38.5) 4 (80) 26 (33) 8 (53) 
Rate† 2.8 5.2 2.8 0.9 1.7 
65+ yrs 
Population 4,095 9,465 55,259 768,014 63,789 
Cases (%)* 0 (0) 1 (8) 1 (20) 47 (60) 2 (13) 
Rate† 0 10.6 1.8 6.1 3.1 
All ages  
Population 56,749 156,286 248,548 4,985,870 731,827 
Cases 1 13 5 78 15 
Rate† 1.8 8.3 2 1.6 2.1 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Rates of disease were highest in N. Canada Aboriginal (99.9 per 100,000) and U.S. Arctic AK Native (64.6) per 
100,000) cases less than two years of age.  In both regions, rates of disease were higher in Aboriginal and AK 
Native populations than in non-Aboriginal and non-Native populations in all age categories. 
 
Haemophilus influenzae by Race and Age Categories, ICS 2012 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,005 1,514 6,196 15,372 Cases (rate†) 4 (99.9) 0 (0) 4 (64.6) 0 (0) 
2-19 Population 33,323 11,915 49,706 137,288 Cases (rate†) 2 (6) 0 (0) 1 (2) 0 (0) 
20-64 Population 47,060 49,004 77,546 381,930 Cases (rate†) 5 (10.6) 0 (0) 5 (6.5) 3 (0.8) 
65+ Population 4,687 4,778 8.997 54,792 Cases (rate†) 1 (21.3) 0 (0) 1 (11.1) 1 (1.8) 
All 
Ages 
Population 89,075 67,210 142,435 589,392 
Cases (rate†) 12 (13.5) 0 (0) 11 (7.7) 4 (0.7) 
*Race unknown in one case <2 years 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation. 
In N. Canada and the U.S. Arctic, the most common clinical presentation associated with H. influenzae was 
pneumonia (60% and 39% of reported cases, respectively).  In Norway, the most common clinical presentation 
was bacteremia (49%). N. Sweden did not report clinical presentation data. 
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2012 Data 
 N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
Pneumonia* 5 (39) 20 (26) 9 (60) 
Bacteremia 1 (8) 38 (49) 2 (13) 
Meningitis 3 (23) 4 (5) 2 (13) 
Septic arthritis 2 (15) 0 (0) 0 (0) 
Epiglottitis 0 (0) 0 (0) 1 (7) 
Amnionitis 0 (0) 0 (0) 1 (7) 
Other/Unknown 2 (15) 16 (20) 0 (0) 
Total 13 78 15 
*with bacteremia 
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Risk Factors 
 
Fifty percent of adult (≥ 18 years) cases of H. influenzae reported in the U.S. Arctic indicated smoking as an 
associated risk factor; 40% indicated alcohol abuse and 20% chronic lung disease as an associated risk factor.  
Fifty percent of adult N. Canadian H. influenzae cases reported chronic lung disease as a risk factor, 33% 
reported diabetes and 17% reported smoking and/or alcohol abuse.  N. Sweden and Norway did not report risk 
factor data. 
 
Vaccination Status 
 
The H. influenzae type b (Hib) conjugate vaccine is required as part of routine childhood vaccination in 
Greenland, N. Canada, N. Sweden, Norway and the U.S. Arctic. There were no cases of Hib reported in a child 
under the age of 5 years in N. Canada, Norway or the U.S. Arctic.  Data on vaccine status were not provided by 
Greenland, N. Sweden and Norway. 
 
Haemophilus influenzae Case Vaccination Status for Hib Vaccine, ICS 2012 Data 
 N. Canada U.S. Arctic 
Total cases* eligible for Hib vaccine† 5 5 
Vaccine status known in cases* eligible for Hib vaccine 4 4 
Cases* eligible for Hib vaccine vaccinated (%)‡ 4 (100%) 4 (100%) 
*All serotypes 
†Children less than 5 years of age 
‡Percent of vaccine status known cases 
 
Serotypes 
 
Haemophilus influenzae Serotypes by Country, ICS 2012 Data 
Serotype N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
a 10 (77) 0 (0) 3 (21) 
b 1 (8) 6 (8) 1 (7) 
e 0 (0) 1 (1) 0 (0) 
f 2 (15) 11 (14) 4 (29) 
Non-typeable 0 (0) 60 (77) 6 (43) 
Total* 13 78 14 
*Number of isolates serotyped 
 
The most common H. influenzae serotype in N. Canada was type a (77% of cases), in Norway and the US 
Arctic, it was type f (14% and 29% of cases, respectively). Non-typeable cases made up a large proportion of 
cases in Norway (77%) and the U.S. Arctic (43%).  Greenland and N. Sweden did not provide serotype data.  
 
Outcome 
 
Four deaths were associated with H. influenzae cases reported to ICS in 2012; three from Norway and one from 
the U.S. Arctic. N. Sweden did not provide outcome data.   
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Haemophilus influenzae Deaths by Country, ICS 2012 Data 
 Norway U.S. Arctic 
No. Deaths 3 1 
Case Fatality Ratio 8%* 7% 
Min-max (yrs) 58.9-85.8 1 case – 0.4 
Serotypes (n) f (1), NT (2) NT (1) 
Clinical 
Presentation (n) Bacteremia (3)  Pneumonia (1) 
*Case outcome unknown in (42) Norway cases 
 
 
Quality Control 
 
Two QC panels of five H. influenzae and N. meningitidis isolates were shipped and serotyped or serogrouped.  
There was one discrepant result which was due to the primer set available that did not include all possible 
serogroups [2]. 
 
Conclusions 
 
Widespread use of Hib conjugate vaccines has led to the virtual disappearance of Hib disease in these 
populations.  Although serotype a is causing a large proportion of disease in the N. American Arctic, it has not 
reached the rates of Hib disease seen prior to vaccine introduction in these regions.  The proportion of disease 
caused by non-typeable organisms continues to be substantial.   
 20 
Neisseria meningitidis 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of N. 
meningitidis during 2012.  A total of 32 cases of invasive disease caused by N. meningitidis were reported to 
ICS.  N. Sweden had the highest disease rate (1.6 per 100,000).  Three deaths associated with N. meningitidis 
were reported from Norway. 
 
Neisseria meningitidis Case Demographics, ICS 2012 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age  
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,749 0 0 No cases No cases No cases 
N. Canada 156,286 2 1.3  1 (50) 3 (0.3-5.8) 0 (0) 
N. Sweden 248,548 4 1.6 2 (50) 54 (51-57) ‡ 
Norway 4,985,870 24 0.5 11 (46) 19.4(0.3-84.6) 3 (13)  
U.S. Arctic 731,827 2 0.3 1 (50) 9.2 (0.3-18) 0 (0) 
Total 6,179,280 32 0.5 15 (47) 27.8 (0.4-91.3) 3 (11) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡N. Sweden did not report outcomes 
 
The following table shows cases and rates stratified by age category.   
 
  Neisseria meningitidis by Age Category, ICS 2012 Data 
Age  N. Canada N. Sweden Norway U.S. Arctic 
<2 
yrs 
Population 5,519 4,473 122,987 21,568 
Cases (%)* 1 (50) 0 (0) 4 (17) 1 (50) 
Rate† 18.1 0 3.3 4.6 
2-19 
yrs 
Population 45,238 47,031 1,125,578 186,994 
Cases (%)* 1 (50) 0 (0) 9 (38) 1 (50) 
Rate† 2.2 0 0.8 0.5 
20-64 
yrs 
Population 96,064 141,785 2,969,291 459,476 
Cases (%)* 0 (0) 1 (25) 8 (33) 0 (0) 
Rate† 0 0.7 0.3 0 
65+ 
yrs 
Population 9,465 55,259 768,014 63,789 
Cases (%)* 0 (0) 3 (75) 3 (13) 0 (0) 
Rate† 0 5.4 0.4 0 
All 
ages 
Population 156,286 248,548 4,985,870 731,827 
Cases 2 4 24 2 
Rate† 1.3 1.6 0.5 0.3 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
In the U.S. Arctic, one case of N. meningitidis occurred in a non-AK Native person (rate 0.2/100,000) and one 
in an AK Native person (rate 0.7/100,000).  In N. Canada, one Nm case occurred in a non-Aboriginal person 
(rate 1.5/100,000) and one in an Aboriginal person (rate 1.1/100,000).  
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive meningococcal bacterial illness.  In cases with multiple 
discharge diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical 
presentation. The most common clinical presentation reported for N. meningitidis cases was meningitis.  N. 
Sweden did not report clinical presentations. 
 
Clinical Presentation of Reported Neisseria meningitidis Cases, ICS 2012 Data 
 N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia  0 (0) 8 (33) 0 (0)) 
Meningitis 2 (100) 13 (54) 2 (100) 
Other 0 (0) 2 (8) 0 (0) 
Unknown 0 (0) 1 (4) 0 (0) 
Total 2 24 2 
*with bacteremia 
 
Serogroups  
 
Twenty-eight of 32 cases of invasive N. meningitidis reported to ICS in 2012 included serogroup data.  The 
table below lists serogroups by country.  N. Sweden did not report serogroup data.   
 
Neisseria meningitidis Serogroups by Country, ICS 2012 Data 
Serogroup N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
B 0 (0) 9 (37.5) 2 (100) 
C 0 (0) 9 (37.5) 0 (50) 
W135 2 (100) 0 (0) 0 (0) 
Y 0 (0) 6 (25) 0 (0) 
Total 2 24 2 
 
Conclusions 
 
Neisseria meningitidis is a relatively uncommon cause of invasive bacterial disease in the circumpolar area 
under surveillance, however, continued surveillance is warranted due to high morbidity and mortality associated 
with outbreaks.
 22 
Group A Streptococcus 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden (Norbotten) and the U.S. Arctic each reported the occurrence of GAS during 
2012.  A total of 76 cases of invasive disease caused by GAS were reported to ICS.  Among regions reporting 
cases, the rate of disease was highest in N. Canada (9 per 100,000) compared to the lowest in N. Sweden (5.6 
per 100,000).  Five deaths were associated with GAS, four in the U.S. Arctic and one in N. Canada. 
 
Group A Streptococcus Case Demographics, ICS 2012 Data 
Country Population # Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,749 0 0 No cases No cases No cases 
N. Canada 156,286 14 9 7 (50) 55.4 (0.5-75.7) 1 (7) 
N. Sweden 248,548 14 5.6 3 (21) 66.5 (19-91) ‡ 
U.S. Arctic 731,827 48 6.6 19 (40) 49.7 (0.3-87.5) 4 (8) 
Total 1,193,410 76 6.4 29 (38) 53.7 (0.3-91) 5 (8.1) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcomes not reported from N. Sweden 
 
When stratified by age, the highest rates of disease occurred in children <2 years in N. Canada (72.5 per 
100,000) and in individuals 65+ years of age in N. Canada (63.4 per 100,000).   
 
Group A Streptococcus by Age Category, ICS 2012 Data 
Age  N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 5,519 4,473 21,568 
Cases (%)* 4 (29) 0 (0) 3 (6) 
Rate† 72.5 0 13.9 
2-19 yrs 
Population 45,238 47,031 186,994 
Cases (%)* 1 (7) 1 (7) 3 (6) 
Rate† 2.2 2.1 1.6 
20-64 yrs 
Population 96,064 141,785 459,476 
Cases (%)* 3 (21) 4 (29) 33 (69) 
Rate† 3.1 2.8 7.2 
65+ yrs 
Population 9,465 55,259 63,789 
Cases (%)* 6 (43) 9 (64) 9 (19) 
Rate† 63,4 15.3 14.1 
All ages  
Population 156,286 248,548 731,827 
Cases 14 14 48 
Rate† 9 5.6 6.6 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  The highest rates of disease occurred 
in N. Canada Aboriginal children <2 years and persons 65 years and older. 
 
Group A Streptococcus by Race and Age Categories, ICS 2012 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal AK Native Non-AK Native 
<2 Population 4,005 1,514 6,196 15,372 Cases (rate†) 4 (99.9) 0 (0) 3 (48.4) 0 (0) 
2-19 Population 33,323 11,915 49,706 137,288 Cases (rate†) 1 (3) 0 (0) 1 (2) 2 (1.5) 
20-64 Population 47,060 49,004 77,546 381,930 Cases (rate†) 3 (6.4) 0 (0) 12 (15.5) 21 (5.5) 
65+ Population 4,687 4,778 8.997 54,792 Cases (rate†) 6 (128) 0 (0) 3 (33.3) 6 (11) 
All 
Ages 
Population 89,075 67,210 142,435 589,392 
Cases (rate†) 14 (15.7) 0 (0) 19 (13.3) 29 (4.9) 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation.  
The most common clinical presentations for GAS cases in N. Canada and the U.S. Arctic were bacteremia and 
cellulitis. N. Sweden did not report clinical presentations.     
 
Clinical Presentation of Reported group A Streptococcus Cases, ICS 2012 Data 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia 2 (14) 13 (27) 
Cellulitis* 5 (36) 11 (23) 
Necrotizing fasciitis 1 (7) 6 (13) 
Pneumonia* 1 (7) 4 (8) 
Septic arthritis 3 (21) 3 (6) 
Empyema 0 (0) 2 (4) 
Endocarditis 0 (0) 2 (4) 
Strep toxic shock 1 (7) 1 (2) 
Pericarditis 0 (0) 1 (2) 
Osteomyelitis 0 (0) 1 (2) 
Endometritis 0 (0) 1 (2) 
Bursitis 0 (0) 1 (2) 
Amnionitis 0 (0) 1 (2) 
Other 0 (0) 1 (2) 
Unknown 1 (7) 0 (0) 
Total 14 48 
*with bacteremia 
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Risk Factors 
 
Cigarette smoking, alcohol abuse and diabetes were the most common risk factors associated with adult (≥18 
years) GAS cases in the U.S. Arctic. Greenland and N. Sweden did not report risk factor data. 
 
Group A Streptococcus Risk Factor/Medical Conditions in Adults*, ICS 2012 Data† 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 0 (0) 12 (29) 
Alcohol Abuse 1 (11) 11 (26) 
Chronic Lung Disease and/or Asthma 1 (11) 6 (14) 
Immunosuppressive Therapy 1 (11) 4 (10) 
Diabetes 1 (11) 13 (31) 
Injection Drug Use 0 (0) 0 (0) 
Asplenia 0 (0) 0 (0) 
Total Adult* Cases 9 42 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Outcome 
 
Four deaths in cases with GAS were reported from the U.S. Arctic (CFR 8%); two occurred in the 20-64 years 
old age category and two in persons ≥ 65.  One death was reported in Canada in a child <2 years of age. N. 
Sweden did not report case outcome data. 
 
Conclusions 
 
These data suggest higher rates in indigenous populations, particularly in young children and older adults.  
Increased awareness of risk may help target improved treatment responses. 
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Group B Streptococcus 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GBS during 2012.  A 
total of 33 cases of invasive disease caused by GBS were reported to ICS.  Greenland, N. Canada and N. 
Sweden reported no cases. Four deaths in the U.S. Arctic were associated with GBS in 2012. 
 
Group B Streptococcus Case Demographics, ICS 2012 Data 
Country Population 
# 
Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,749 0 0 No cases No cases No cases 
N. Canada 156,286 0 0 No cases No cases No cases 
N. Sweden 248,548 0 0 No cases No cases No cases 
U.S. Arctic 731,827 33 4.5 20 (61) 54.6 (0-80.9) 4 (12) 
Total 1,193,410 33 2.8 20 (61) 54.6 (0-80.9) 4 (12) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
 
When stratified by age, the highest rates of disease in the U.S. Arctic occurred in cases less than two years of 
age.   
 
Group B Streptococcus by Age Category, ICS 2012 Data 
Age  U.S. Arctic 
<2 yrs 
Population 21,568 
Cases (%)* 5 (15) 
Rate† 23.2 
2-19 yrs 
Population 186,994 
Cases (%)* 0 (0) 
Rate† 0 
20-64 yrs 
Population 459,476 
Cases (%)* 17 (52) 
Rate† 3.7 
65+ yrs 
Population 63,789 
Cases (%)* 11 (33) 
Rate† 17.2 
All ages  
Population 731,827 
Cases 33 
Rate† 4.5 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
 
There were three cases of early-onset disease (cases less than 7 days old) in the U.S. Arctic (0.3 cases per 1,000 
live births). 
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Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  No cases were reported in 2012 in N. 
Canada.  The overall rates of disease caused by GBS were higher in AK Native people compared to non-Native 
people.  The highest rates of disease occurred in AK Native children less than 2 years old. 
 
Group B Streptococcus by Race and Age Categories, ICS 2012 Data 
Age 
(yrs) 
 U.S. Arctic 
Native Non-Native 
<2 Population 6,196 15,372 Cases (rate*) 2 (32.3) 3 (19.5) 
2-19 Population 49,706 137,288 Cases (rate*) 0 (0) 0 (0) 
20-64 Population 77,546 381,930 Cases (rate*) 7 (9) 10 (2.6) 
65+ Population 8,997 54,792 Cases (rate*) 2 (22.2) 9 (16.4) 
All 
Ages 
Population 142,435 589,392 
Cases (rate*) 11 (7.7) 22 (3.7) 
*Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation.  
In the U.S. Arctic, bacteremia (30%) was the most common clinical presentation reported for cases of GBS in 
2012 followed by cellulitis (27%) and pneumonia (12%).   
 
Clinical Presentation of Reported group B Streptococcus Cases, ICS 2012 Data 
 U.S. Arctic 
n (%) 
Bacteremia 10 (30) 
Cellulitis* 9 (27) 
Pneumonia* 4 (12) 
Septic arthritis 3 (9) 
Amnionitis 3 (9) 
Endocarditis 1 (3) 
Empyema 1 (3) 
Osteomyelitis 1 (3) 
Other 1 (2.5) 
Total 33 
*with bacteremia 
 
Risk Factors 
 
Forty-six percent of GBS adult (≥ 18 years) cases reviewed in the U.S. Arctic indicated diabetes as a risk factor 
in 2012; 18% were smokers, 14% had chronic lung disease and/or reported alcohol abuse.   
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Outcome 
 
Four deaths in cases with GBS were reported in the U.S. Arctic (CFR 12%); 1 occurred in the <2 year old age 
group, 2 in the 20-65 years age category and 1 in the 65+ years age category.   
 
Conclusions 
 
Guidelines for universal screening of pregnant women for GBS carriage were established in 2002 which have 
resulted in decreases in early onset disease.  Cases continue to occur in older age groups which warrants 
continued surveillance.
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CONCLUSIONS 
 
Monitoring rates of disease and levels of antimicrobial resistance in S. pneumoniae, H. influenzae, N. 
meningitidis, GAS and GBS via use of the ICS system is important in providing data on groups at risk for 
disease, measurement of effectiveness of prevention measures, and emerging challenges in serotype distribution 
and antimicrobial resistance.  Efforts to expand ICS to include all circumpolar nations will continue. 
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PARTICIPANTS 
 
International Circumpolar Surveillance (ICS) Participants, 2012 
 
FINLAND 
Reference 
Laboratory 
National Public Health Institute (KTL) Laboratory, Oulu 
Laboratories Et.-Pohjanmaan sh-piiri, Seinäjoen sairaalan mikrobiol. lab. 
Etelä-Karjalan keskussairaalan kl.mikrobiologian laboratorio 
HY – Serobakteriologian laitos 
Jorvin sairaala, kliinisen mikrobiologian laboratorio 
KYS – Mikrobiologian laboratorio 
Kainuun keskussairaalan mikrobiologian laboratorio 
Kanta-Hämeen keskussairaalan mikrobiologian laboratorio 
Keski-Pohjanmaan keskussairaalan mikrobiologian laboratorio 
Keski-Suomen keskussairaalan mikrobiologian laboratorio 
Kymenlaakson keskussairaalan mikrobiologian laboratorio 
Lapin keskussairaalan mikrobiologian laboratorio 
Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 
Vaasan keskussairaalan mikrobiologian laboratorio 
 
GREENLAND 
Reference 
Laboratories 
Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 
Laboratories Nanortalik Hospital 
Qaqortoq Hospital 
Narsaq Hospital 
Paamiut Hospital 
Maniitsoq Hospital 
Sisimut Hospital 
Aasiaat Hospital 
Qasigiannguit Hospital 
Ilulissat Hospital 
Qeqertarsuaq Hospital 
Uummannaq Hospital 
Upernavik Hospital 
Qaanaaq Hospital 
Ammassalik Hospital 
Ittoqqortoormiit Hospital 
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ICELAND 
Reference 
Laboratory 
Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital 
Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 
Regional Hospital Neskaupstadur 
 
NORTHERN CANADA 
Laboratory Centre 
for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK 
Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK 
Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 
IMPAct Coordinator, Vaccine Evaluation Centre, Vancouver, BC 
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NORTHERN SWEDEN 
Reference 
Laboratory 
Department of Bacteriology, Swedish Institute for Infectious Disease 
Control, Stockholm 
Laboratories Department of Microbiology, Sunderby Hospital, Lulea 
 
NORWAY 
Reference 
Laboratory 
Oslo/Tromsö 
Laboratories Frederikstad, Østf. SSH 
Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 
Dr. Willes med.lab. 
Radiumhospitalet 
Folkehelsa, vir.lab. 
Folkehelsa, bakt.lab. 
Forsv.mik.lab.Folk.h. 
Rikshospitalet, mik.lab. 
Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 
Kirkenes SH, mik.lab. 
Laboratorium INA/div. 
Haugesund, mik.lab. 
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U.S. ARCTIC 
Reference 
Laboratory 
Arctic Investigations Program, National Center for Emerging and 
Zoonotic Infectious Diseases, Centers for Disease Control and 
Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK 
Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
 
